cyrilzakka/clinical-trials huggingface dataset:
Influence of Mango Intake of Skin Health in Postmenopausal Women

This study aims to investigate the effects on 16 weeks of mango intake on skin health in postmenopausal women. Half of the participants will receive 85g portions of mangoes while the other half receive 250g portions of mangos. Participants will be instructed to consume the specific portion 4 times a week, for a total duration of 16 weeks.

Mangoes are rich in carotenoids, flavonoids, vitamins and other active phytochemicals such as resistant starches. Although a role of mangoes in skin health has long been advocated in traditional medicine, little scientific research has been conducted.

We hypothesize that 85g (0.5 cups) of mango intake for 16 weeks will have minimal impact on skin health, while 250g (1.5 cups) of mango intake will produce significant benefits.

Eligibility Criteria:
Inclusion Criteria:

* Postmenopausal
* Fitzpatrick skin type I and II
* BMI 18.5 - 35.0 kg/m2
* Normal blood levels in the comprehensive metabolic panel, or values slightly out of range as approved by the study physician

Exclusion Criteria:

* Allergic to mangoes
* Fruit consumption of 2 or more cups per day
* Vegetable consumption of 3 or more cups per day for females
* Fruit juice consumption of more than 1 cup per day
* Self-reported malabsorption
* Currently taking regular prescription drugs i.e. statins, thyroid, anti-inflammatory drugs
* Had any medical or cosmetic procedures such as laser resurfacing or plastic surgery to the face within the last 6 months, including botulinum toxin, dermal fillers, collagen or other similar cosmetic procedure
* Autoimmune photosensitive condition or known genetic condition with a deficiency in collagen production (such as Ehler-Danlos)
* Smoking (current smoker, smoked within the past year, former smokers with greater than a 20 pack-year history of smoking within the past 20 years.
* Indications of substance or alcohol abuse
* Unwillingness to discontinue high antioxidant supplements during washout and interventions
HeartLight X3 Endoscopic Ablation System With Excalibur Balloon for Treatment of Symptomatic Persistent AF

The objective of the study is to demonstrate the improved ablation and procedure times of the HeartLight X3 compared to the original HeartLight catheter in the treatment of persistent atrial fibrillation.


Eligibility Criteria:
Inclusion Criteria:

* early persistent AF, failure of at least one AAD, others

Exclusion Criteria:

* overall good health as established by multiple criteria
Efficacy of Platelet-rich Plasma (PRP) in the Treatment of Dark Circles Under the Eyes

10 ml of blood from each patient will be drawn. This blood specimen will be centrifuged in a specific way to get 1 ml of platelet rich plasma (PRP). PRP will be injected into the the skin under the eyes. The treatment course consists of three sessions of PRP injections with one-month intervals between the sessions.

Background:

Dark circles around the eyes is a common problem pretending with relatively dark eyelids concerns many patients, especially women, because of the inconvenience caused by esthetic and negative impact on the psyche and the patient's quality of life. There are several causing factors (such as sun exposure, smoking, alcohol, sleep deprivation, genetic and structural factors). variety of treatments have been used for this situation , but without clear results.

The term 'Platelet-Rich Plasma (PRP)' is a general term used to describe hanging plasma that has been obtained from whole blood with concentration of platelets higher than normal concentration found in the circulating blood. PRP's work mechanism depends on the fact that platelets contain important substances called (growth factors), which have a known role in the process of reform and renewal of tissues.

Aim of the research:

This study was designed to evaluate the effectiveness of (PRP) injection in the treatment of dark circles under the eyes. This is an uncontrolled open therapeutic trial study which will be performed at the Hospital of Dermatology and Venereology of Damascus University in Damascus, Syria during the period from June 2016 to June 2017.

The results will be assessed by standardized digital photography month after each injection and three months after the latest assessment with the assistant of skin colors scale. In addition, the patient's satisfaction with the results and any treatment-related side effects will be recorded.

Eligibility Criteria:
Inclusion Criteria:

* Patients with periorbital hyperpigmentation

Exclusion Criteria:

* patients with known platelet dysfunction syndrome
* patients with platelet count less than 100,000 ul
* patient with hemodynamic instability
* patients with severe systemic illness or malignancy or chronic medical illness (e.g. diabetes, chronic infections, and blood dyscrasias).
* patients with local skin disorders or active herpes infection at the site of the procedure.
* patients on anti-coagulants therapy or non-steroidal anti-inflammatory drugs (NSAID) within 48 hours of procedure,
* patients with corticosteroid injection at treatment site within 1 month, systemic use of corticosteroids within 2 weeks
* patients with recent fever or illness, and hemoglobin level\< 10 g/dl.
* pregnancy
* history of keloidal scarring.
IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics

A Phase 1 Open Label Single Center Safety, Tolerability and Pharmacokinetic Study of IS-001

A Phase 1 Open Label Single Center Safety, Tolerability and Pharmacokinetic Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy Using the da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging

Eligibility Criteria:
Inclusion Criteria:

1. Subject is between the ages of 18 and 65.
2. Subject is scheduled to undergo robotic hysterectomy using a da Vinci® Si/Xi surgical system with Firefly® fluorescent imaging.
3. Subject is willing and able to provide informed consent.
4. Subject is considered capable of complying with study procedures.
5. Subject has no medical history of liver or kidney disease.
6. Subject has no evidence of NYHA Class II-IV cardiac disease.
7. Subject has recent (\< 3 months) clinical hematology (CBC) values within the acceptable values reference range.
8. Subject has recent (\< 3 months) clinical serum chemistry (CMP) values within the acceptable values reference range.

Exclusion Criteria:

1. Subject is pregnant or nursing.
2. Subject has a history of alcoholism.
3. Subject has a history of drug abuse.
4. Subject has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
5. Subject has known human immunodeficiency virus (HIV) infection.
6. Subject has been diagnosed with or treated for cancer in the last 2 years.
7. Subject has a total body weight \< 32 kg.
8. Subject has after 5 minutes of supine rest a diastolic blood pressure ≥100 mmHg and/or a systolic blood pressure ≥160 mmHg.
9. Subject has after 5 minutes of supine rest a resting heart rate ≤35 or ≥115 bpm.
10. Subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data or represents an unacceptable safety liability.
Influence of Obesity on Microvascular Reactivity During General Anesthesia

The purpose of this study was to investigate the effect of obesity on changes in microvascular reactivity and tissue oxygen saturation (StO2) during general anesthesia using near-infrared spectroscopy in conjunction with vascular occlusion tests (VOT).

For this prospective observation investigation, a total of 128 patients who underwent elective surgery under general anesthesia at Pusan National University Hospital between June 2018 and February 2021 were participated in this study. Baseline StO2 on thenar eminence, hemodynamics, and laboratory profile were monitored before (Tpre) and 30 min after general anesthesia (Tpost). During vascular occlusion tests (VOT), the occlusion slope representing oxygen consumption of muscle and recovery slope representing microvascular reactivity were also collected at Tpre and Tpost. For analysis, the patients were divided into two groups: overweight (body mass index \[BMI\] ≥ 25 kg/m2) and normal weight (BMI \< 25).

Preoperative laboratory findings were obtained. Mean blood pressure (MBP), pulse oxygen saturation (SpO2), heart rate (HR), skin temperature, and VOT-derived measurements, including baseline tissue oxygen saturation (StO2), occlusion slope, minimum StO2, time to minimum StO2, recovery slope, maximum StO2, and time to baseline StO2 were recorded before (Tpre) and 30 min after general anesthesia (Tpost).

Eligibility Criteria:
Inclusion Criteria:

* Subjects who underwent elective surgery under general anesthesia.

Exclusion Criteria:

* Society of Anesthesiologists (ASA) physical status \> II
* patients with a neuraxial block
* uncontrolled hypertension
* patients with major cardiovascular disease
* diabetes
* pregnant individuals
* peripheral vascular disease
* chronic venous insufficiency
* smoking: Pack-years \> 10
* chronic obstructive and restrictive pulmonary disease
Diagnosis and Percutaneous Treatment of Biliary Tract Diseases

This study aims to implement and optimize the treatment of bile duct diseases in participants not eligible for endoscopic treatment using the Spyglass system, a system suitable for diagnostic and therapeutic endoscopic procedures in the pancreatic-biliary system, including the hepatic ducts.

The main question it aims to answer is:

- Can the percutaneous cholangioscopic assisted technique resolve the biliary litiasis and/or perform endobiliary biopsies in less time than the traditional technique?

Participants will undergo a colangioscopic-assisted treatment using the SpyGlass mini-endoscopic system at the Addomino-pelvic diagnostic and interventional radiology UOC of the Bologna University Hospital.

This is a pilot, spontaneous, non-pharmacological, prospective and single-center interventional study aimed at participants with bile duct diseases not eligible for endoscopic treatment, who, once enrolled, will undergo percutaneous colangioscopic-assisted treatment at the Addominal-pelvic diagnostic and interventional radiology UOC of the University Hospital of Bologna. After a 24-month enrollment phase, a 36-month follow-up phase will be undertaken to assess the functional and therapeutic outcomes of this approach.

The enrollment and the collection of informed consent will be carried out by the Radiologists involved in the study who will also take care of the collection of clinical data and the review of all pseudoanymous radiological images pre/post treatment in order to evaluate the outcome of percutaneous treatment, the number of treatments, the duration of drainage stay, the relapse-free interval and the length of hospitalization. Participants in the study will undergo treatments commonly used in daily clinical practice, including biliary clearance and/or endobiliary biopsy.

Eligibility Criteria:
Inclusion Criteria:

* Radiological diagnosis of indeterminate gallstones or stenosis of the bile ducts not eligible for endoscopic treatment and/or previous failed endoscopic treatment
* Good liver function (hemoglobin, hematocrit, GOT, GPT, GGT within normal ranges)
* Age over 18
* Obtaining informed consent

Exclusion Criteria:

* presence of severe untreatable coagulopathies
Real-World Study of Iruplinalkib in the Treatment of ALK-Positive Non-Small Cell Lung Cancer

This study is a national multicenter real-world investigation aimed at evaluating the real-world effectiveness and safety of Iruplinalkib in the treatment of ALK-positive NSCLC in China.

The study aims to enroll ALK-positive NSCLC patients who have undergone treatment with Iruplinalkib prior to enrollment. Demographic information, medical history, Iruplinalkib-containing treatment regimens, clinical outcomes, adverse events, and related data will be collected for all enrolled patients.

As this study is a real-world investigation, treatment procedures, visit schedules, and examinations will be based on the routine clinical practice of physicians. The primary sources of data for this study will mainly consist of patients' routine medical records or healthcare documentation.


Eligibility Criteria:
Inclusion Criteria:

* Patients willingly contribute their clinical data for this study
* Patients with ALK-positive non-small cell lung cancer
* Age ≥ 18 years
* Patients who have undergone treatment with Iruplinalkib.

Exclusion Criteria:

* Known pregnant or lactating females
* Patients with interstitial lung diseases, drug-related pneumonitis, or radiation pneumonitis require ongoing medical intervention.
Effect of Proton Pump Inhibitor and Mosapride on Acid Pocket in Gastroesophageal Reflux Disease

The gastric acid pocket is believed to be the reservoir from which acid reflux events originate. The risk for acidic reflux is mainly determined by the position of the gastric acid pocket. Little is known about how changes in position and size of the acid pocket contribute to the therapeutic effect of proton pump inhibitors(PPI) plus mosapride in patients with gastroesophageal reflux disease. Investigators will conduct a prospective randomized, single blind and placebo-controlled clinical trial to evaluate the hypothesis that mosapride affecting gastric motility might reduce gastro-esophageal reflux by changing the acid pocket position and size.


Eligibility Criteria:
Inclusion Criteria:

* Patients with diagnosed GERD(gastro-esophageal reflux disease), defined by the presence of oesophagitis obtained during a previous upper endoscopy or typical GERD symptoms(heartburn, acid reflux).

Exclusion Criteria:

* who had organic gastrointestinal disease including inflammatory bowel disease, cancer and ulcer
* who took drugs which could affect evaluation of the treatment; other PPIs, H2RAs(H2 receptor antagonists), prokinetics,mucosal protective agents, antacids, cholinergic and anticholinergic agents, and antidepressants for at least 4 weeks prior to study start
* who had severe systemic diseases including hepatic and nephrotic disease
* who had previous gastrectomy history
* who was in state of pregnancy
Detection of Meconium in Amniotic Fluid in Post Term Pregnancies

Meconium constitutes the bowel contents of the fetus and is normally expelled only after birth. However, it may be secreted into the amniotic fluid of 20% of all fetuses. Meconium Stained Amniotic Fluid had been recognized from ancient times as an obstetric hazard which complicates delivery and is associated with increased newborn morbidity and mortality. At present there is no viable diagnostic test for Meconium prior to the onset of labor and the rupture of membranes. The system developed for the detection of Meconium, based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength. The diagnostic test being developed does not require penetration into the amniotic sac and is safe, painless and simple to perform.


Eligibility Criteria:
Inclusion Criteria:

* 37-42 weeks regnancy without rupture of membranes

Exclusion Criteria:

* none
Cough in Eastern and Central Finland

Comparison of citric acid and mannitol cough provocation tests among subjects with chronic cough and healthy volunteers.

35 subjects with chronic cough plus 25 subjects without any cough will be asked to participate. The study consists of two visits in the outpatient clinic of Kuopio University Hospital, department of respiratory medicine, 2 - 7 days apart. They will fill in the Leicester Cough Questionnaire and undergo two different cough provocation tests, in random order: Mannitol test and citric acid test. If a chest x-ray has not been taken within 6 months, it will be taken.

Eligibility Criteria:
Inclusion Criteria, Chronic cough patients:

(both criteria must be fulfilled)

* presence of current chronic cough (\> 8 weeks)
* Leicester Cough Questionnaire total score \< 17

Inclusion criteria, healthy volunteers

* absence of any form of cough

Exclusion Criteria:

* age \< 18 years
* any disability which would challenge the subject's ability to understand the purpose and methods of the study
* pregnancy
* breastfeeding
* current smoking or ex smoking more than 10 pack years
* any thoracic x-ray finding indicating urgent mediacal interventions
ADDRESS - Adult Deformity Robotic vs. Freehand Surgery to Correct Spinal Deformity

To quantify potential short- and long-term benefits of robotically-guided minimally invasive (MIS) or open-approach spine surgery in adult patients undergoing multi-level spinal instrumentation surgery, in comparison to image- or navigation-guided instrumentation in a matching cohort of control patients, performed using a freehand technique, both in MIS and open approaches.


Eligibility Criteria:
Inclusion Criteria:

1. Adult patients (age 21 years and older), undergoing long (5 consecutive vertebrae or more) spinal fusion surgery, between T1 to the sacrum.
2. Cases may include surgeries involving iliac screws (e.g., Galveston technique or S2AI screws) although these screws will not be included in the data analysis.
3. Cases may include augmented cases (when one or more of the screws are inserted into vertebrae after a vertebral augmentation procedure, such as kyphoplasty or vertebroplasty).
4. Patient capable of complying with study requirements
5. Signed informed consent by patient

Exclusion Criteria:

1. Infection or malignancy
2. Primary abnormalities of bones (e.g. osteogenesis imperfecta)
3. Primary muscle diseases, such as muscular dystrophy
4. Neurologic diseases (e.g. Charcot-Marie Tooth, Guillain-Barre syndrome, cerebral palsy, spina bifida, or neurofibroma)
5. Spinal cord abnormalities with any neurologic symptoms or signs
6. Spinal cord lesions requiring neurosurgical interventions, such as hydromyelia
7. Paraplegia
8. Patients who have participated in a research study involving an investigational product in the 12 weeks prior to surgery
9. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study.
10. Pregnancy
11. Patient cannot follow study protocol, for any reason
12. Patient cannot or will not sign informed consent
Effect of Sugammadex for Muscle Motor Response and Awareness in Intraoperative Wakeup

The study will be performed to evaluate motor response and awareness with using sugammadex during wakeup procedure in spine surgery. The investigator's goal is to investigate the effect of sugammadex on the state of consciousness and motor-somatosensorial evoked potentials.

Between 10-25 age, American Society of Anesthesiologist clinical status(ASA) I-II, 60 patient which will be performed spine surgery in orthopedics clinic will be enrolled in this study. Patient will be randomized into two group that include 20 patient. General anesthesia will be administered by Totally intravenous anesthesia (TIVA) with propofol and remifentanyl for all patients. Two groups will be monitored with BIS (bispectral index), TOF (train-of-for) MEP (motor evoked potential) and SSEP (somatosensorial potential). During wakeup procedure, in group S, TIVA will be stopped and 2 mg/kg of sugammadex will be given intravenously. BIS, TOF, MEP, SSEP will be measured. In group N, TIVA will be stopped and 0.04 mg/kg of neostigmine will be given. Also BIS, TOF, MEP, SSEP will be measured. Sugammadex will be given group S and Neostigmine will be given group N at the end of the operation. At postoperative sixth hour, the investigators will visit all the patients and ask standard questions about intraoperative wakeup procedure.

Eligibility Criteria:
Inclusion Criteria:

* American society of anesthesiologists (ASA) physical status I-II patients
* spine surgery
* 10-25 age

Exclusion Criteria:

* ASA III and above
* Patient refusal
* neuromuscular disease
Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity

Stroke is one of the leading cause of death and disability worldwide. Post-stroke spasticity (PSS) is outbreak after a stroke and is featured by disabling muscle stiffness. PSS could manifest in up tp 50% cases within 6 months after a stroke, especially in the upper limb. Despite it is an acknowledged condition it is insufficiently recognized and treated in clinical practice.

Focal and regional spasticity could improve with rehabilitation and in selected cases with botulinum neurotoxin (BoNT) type A injections. The latter causes muscle relaxation and fosters neuroplasticity, which is able in turn of ameliorating several patient functional aspects. Recent literature demonstrated that PSS patients treated with early BoNT (within 3 month since PSS outbreak) could improve in their clinical status better than patients with a later treatment.

An earlier recognition of PSS predictors could improve patient management. Hence, the investigators are going to perform a multicentric prospective observational real life study with BoNT, based on the best clinical practice and aimed at the early recognition and management of PSS through the identification of 1) early clinical predictors of spasticity (collected within 10 days since stroke), 2) BoNT clinical outcome relative to the timing of the treatment


Eligibility Criteria:
Inclusion Criteria:

* Ischemic stroke with onset not far than 10 days before the enrollment
* BoNT naive
* Ability to sign the informed consent

Exclusion Criteria:

* Hypersensitivity to BoNT or BoNT related substances
* Participant of Post-stroke spasticity RCT
* Persistent and severe altered mental status or concurrent severe medical condition able to hasten the rehabilitation path.
Optimal Depth for Esophageal Stethoscope

The purpose of the present study was to evaluate the optimal insertion depth of an esophageal stethoscope with a thermistor for core temperature monitoring.

Monitoring core temperature is crucial for maintaining normothermia during general anesthesia. During anesthesia, an esophageal stethoscope with a thermistor for monitoring esophageal temperature is frequently used.

There are several researches on the depth or position of the esophageal stethoscopes, but there is only limited information (known as about 40-45 cm or T8-T9).

The purpose of the present study was to evaluate the optimal insertion depth of an esophageal stethoscope with a thermistor for core temperature monitoring.

Eligibility Criteria:
Inclusion Criteria:

* The patients with ASA class 1-2 (20-65 years old) who are undergoing elective surgery with supine or lithotomy position, without position change scheduled to last more than 90 min.

Exclusion Criteria:

* anatomical abnormality with the upper airway
* risks of a difficult airway
* abnormal central anatomical structures such as airway, diaphragm, or spine on the chest X-ray
* history of disease or surgery on the stomach or esophagus
* risks of bleeding or coagulopathy on the preoperative laboratory results
* obese patients with BMI over 30
* contraindication to insertion of ES for the surgery
* who did not take a standing chest PA X-ray before surgery
* position change during the surgery
* open chest surgery
The Role of Netrin -1 in Acute Coronary Syndrome

In our study, Netrin -1; We found that patients with ACS increased at the time of admission, decreased TIMI 3 flow after angiography, and higher risk groups in high risk groups such as TIMI and GRACE were found to have higher Netrin-1 levels.


Eligibility Criteria:
Inclusion Criteria:

* Patients over the age of 18
* diagnose ACS
* patients undergoing angiography

Exclusion Criteria:

* CVE history
* Neurological disease
* Pregnancy and Lactation
* Liver failure
* Diagnosed malignity
* Use of anticonvulsant and nephrotoxic medication
* Chronic kidney disease
* Not having angiography
* Developing acute renal failure after angiography
* Patients who rejected to participate were excluded.